Ahead of CES 2026, DEEPX, a pioneer in ultra-low-power on-device AI semiconductors, announced the official launch of the DX-H1 vision neural processing unit (V-NPU), a dedicated video intelligence ...
TransCode Therapeutics ( (RNAZ)) just unveiled an announcement. On December 19, 2025, TransCode Therapeutics appointed veteran life sciences executive Jack E. Stover to its board of directors, ...
BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, ...
TransCode Therapeutics ( (RNAZ)) has shared an announcement. On December 11, 2025, TransCode Therapeutics announced a collaboration with Quantum Leap Healthcare Collaborative to evaluate their lead ...
BOSTON, Dec. 11, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate TransCode's ...
A controversy is swirling at a Texas university. The trigger? A flowchart. On Dec. 1, the new chancellor of the Texas Tech University system sent professors a diagram laying out a chain of approval ...
TransCode acquires 100% of the issued and outstanding interests of Polynoma from CK Life Sciences Concurrent equity investment of $25 Million from CK Life Sciences into TransCode TransCode expands its ...
(RTTNews) - TransCode Therapeutics (RNAZ) has entered into a definitive agreement to acquire Polynoma, a privately-held biotechnology immuno-oncology company. Polynoma is developing a late-stage ...
In a pair of deals, TransCode Therapeutics has bagged Polynoma and its phase 3 cancer vaccine, as well as a $25 million injection into its cash-strapped coffers—but in doing so, the company is trading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback